Predicting Prognosis and Immunotherapy Response in Glioblastoma (GBM) With a 5‐Gene <scp>CAF</scp>‐Risk Signature
The 5-gene CAF-risk signature exhibited accurate prognostic predictions and efficiently evaluated clinical immunotherapy responses among GBM patients. These results offer robust evidence regarding the implication of CAF in GBM and underscore the potential clinical value of personalized anti-CAF therapies in conjunction with immunotherapy.
Authors
- Rui Shi (ORCID: https://orcid.org/0000-0001-5412-6926)
- Luqing Tong (ORCID: https://orcid.org/0000-0003-0203-037X)
- Shengxiang Zhang (ORCID: https://orcid.org/0000-0001-6524-9673)
- Min Yan (ORCID: https://orcid.org/0000-0002-7775-3153)
- Haifeng He (ORCID: https://orcid.org/0009-0007-7076-1082)
- Ke Ye (ORCID: https://orcid.org/0000-0002-6343-0054)
- Yu Zhu (ORCID: https://orcid.org/0000-0003-1133-8376)
- Renya Zhan
Institutions
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/cnr2.70158
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation